Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Colorcon
Mallinckrodt
Baxter
Harvard Business School

Last Updated: August 17, 2022

CLINICAL TRIALS PROFILE FOR PROPECIA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Propecia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00381108 ↗ Study of the Effects of Pomegranate Tablets on Enlarged Prostates Unknown status Jarrow Pharmaceuticals Phase 1 2005-09-01 To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
NCT00381108 ↗ Study of the Effects of Pomegranate Tablets on Enlarged Prostates Unknown status Pomegranate Health Phase 1 2005-09-01 To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
NCT00381108 ↗ Study of the Effects of Pomegranate Tablets on Enlarged Prostates Unknown status University of California, Irvine Phase 1 2005-09-01 To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
NCT00837252 ↗ Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed National Eye Institute (NEI) Phase 1/Phase 2 2009-02-01 Central serous chorioretinopathy (CSC) is a retinal disorder characterized by an accumulation of serous fluid under the retina. Although acute CSC tends to spontaneously resolve on its own with minimal sequelae, chronic CSC tends to persist and lead to irreversible visual loss. The pathogenesis of CSC is complex; however, systemic androgens have been implicated. Finasteride is an anti-androgen medication that is widely used in the treatment of various conditions. The objective of this study was to investigate the safety and potential efficacy of oral finasteride as a treatment for chronic CSC. Five participants with chronic CSC were enrolled into this uncontrolled, unmasked, Phase I/II study. An oral dose of finasteride, 5 mg daily, was administered to all participants for three months. Following this, finasteride was withheld and participants were observed for another three months. If a participant experienced a beneficial effect during the period in which he received finasteride and then experienced a relapse during the observation period, finasteride was re-instituted for the remaining period of the study. Relapse was defined as a return to the baseline maximum lesion height and/or return to baseline lesion volume.
NCT00842751 ↗ Oral T7 Oral Testosterone in Man Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 2009-07-01 The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.
NCT00842751 ↗ Oral T7 Oral Testosterone in Man Completed National Institutes of Health (NIH) Phase 2 2009-07-01 The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Propecia

Condition Name

Condition Name for Propecia
Intervention Trials
Healthy 2
Prostate Cancer 2
Alopecia, Androgenetic 1
Androgenetic Alopecia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Propecia
Intervention Trials
Alopecia 2
Prostatic Neoplasms 2
Prostatic Hyperplasia 1
Alopecia Areata 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Propecia

Trials by Country

Trials by Country for Propecia
Location Trials
United States 6
Canada 2
Germany 1
Spain 1
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Propecia
Location Trials
Illinois 1
Missouri 1
Kansas 1
Washington 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Propecia

Clinical Trial Phase

Clinical Trial Phase for Propecia
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
Phase 1/Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Propecia
Clinical Trial Phase Trials
Completed 6
Active, not recruiting 1
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Propecia

Sponsor Name

Sponsor Name for Propecia
Sponsor Trials
Dr. Reddy's Laboratories Limited 2
University of Chicago 1
Polichem S.A. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Propecia
Sponsor Trials
Other 5
Industry 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Moodys
Mallinckrodt
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.